BREAKING NEWS: First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study
LEARN MORE
Istari Oncology Participates in Virtual Investor Conferences
LEARN MORE
Istari Oncology Initiates Its Phase 1/2 Sub-Study Evaluating PVSRIPO in Patients with Head and Neck Cancer
LEARN MORE
Breaking News: PVSRIPO Receives Fast Track Designation in Advanced Melanoma
LEARN MORE
Jamie Iudica Joins Istari Oncology as Chief Manufacturing Officer
LEARN MORE
PVSRIPO Phase 1 Melanoma Trial Published in JITC
LEARN MORE
Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of Clinical Oncology 2021 Annual Meeting
LEARN MORE
FDA Clears IND for LUMINOS-103 Basket Trial for PVSRIPO
LEARN MORE
First Patient Dosed in LUMINOS-102
LEARN MORE
New Study Shows PVSRIPO Leads to Robust, Polyfunctional T Cells
LEARN MORE
Orphan status granted to PVSRIPO for advanced melanoma
LEARN MORE
Watch our latest video about PVSRIPO's mechanism of action
VIEW HERE
Breaking News: Istari Oncology Honored as
“Best Early Stage Product Development Company” by Triangle Business Journal LEARN MORE
Revolutionizing cancer care.
PVSRIPO is an investigational intratumoral immunotherapy based on the Sabin type-1 polio vaccine. Learn more about how this novel approach to viral immunotherapy could provide a safer, more effective approach to immune activation against cancer.
Reshaping the Standard of Care for the Treatment of Cancer
Istari Oncology is a clinical-stage biotechnology company focused on developing and commercializing groundbreaking immuno-oncology therapies with the potential to improve the standard of care for a wide range of solid tumors, including glioblastoma and melanoma.
TECHNOLOGIES IN CLINICAL DEVELOPMENT
Polio Virus Sabin-Rhinovirus Poliovirus (PVSRIPO)
Antibody Toxin Conjugates (ATCs)
OUR SCIENCE
Find out more about our breakthrough PVSRIPO platform
PIPELINE
For more on how our technologies are advancing
NEWS
Access the latest updates and research